Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. reported a routine equity compensation grant linked to director Tomas Kiselak and Fairmount Funds Management LLC. A stock option was awarded representing the right to buy 7,657 shares of common stock at an exercise price of $85.00 per share.
The option vests on the one-year anniversary of the grant date, conditioned on Mr. Kiselak’s continued service. According to the footnotes, he holds the option for one or more investment vehicles managed by Fairmount, must deliver any net cash or stock to Fairmount, and therefore disclaims beneficial ownership, while Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Apogee Therapeutics director Nimish P. Shah reported a grant of stock options covering 7,657 shares of common stock, with an exercise price of 85.00 and expiration on 2036-06-09. The options vest on the one-year anniversary of the 2026-06-09 grant date.
Under an agreement, the option and underlying shares are held for the sole benefit of Venrock Management, LLC, which directs any exercise and is entitled to the shares. Shah may be deemed an indirect beneficial owner only to the extent of his pecuniary interest.
Apogee Therapeutics director Mark C. McKenna received a grant of stock options covering 7,657 shares of common stock at an exercise price of $85.00 per share. The options vest on the one-year anniversary of the June 9, 2026 grant date, contingent on his continued service, and expire on June 9, 2036.
Apogee Therapeutics director William A. Jones Jr received a grant of stock options giving him the right to buy 7,657 shares of Apogee common stock at an exercise price of $85.0000 per share. These options were awarded as compensation, not purchased in the open market, and expire on June 9, 2036. The award will fully vest on the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. After this grant, he directly holds options covering 7,657 underlying shares.
Apogee Therapeutics director Jennifer A. Fox received a new stock option grant. She was awarded options to buy 7,657 shares of common stock at an exercise price of $85.0000 per share. The option vests on the one-year anniversary of the grant date and expires on June 9, 2036, reflecting a compensation-related award rather than an open-market purchase or sale.
Apogee Therapeutics director Lisa Bollinger received a stock option grant for 7,657 shares of common stock on June 9, 2026. The option has an exercise price of $85.00 per share and expires on June 9, 2036. All 7,657 options will vest on the one-year anniversary of the grant date, contingent on her continued service, and represent her total option holdings reported in this filing.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an option exercise and related stock sale. He exercised stock options covering 4,125 shares of common stock at $22.86 per share, then sold 5,500 shares in an open-market transaction at $78.71 per share.
Following these transactions, he directly holds 205,648 shares of common stock and retains stock options representing the right to purchase 118,915 shares, expiring on December 18, 2033. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, and represents a small portion of his overall holdings.
Apogee Therapeutics entered a major financing collaboration with Blackstone Life Sciences built around future sales of its anti‑IL‑13 antibody zumilokibart. Under a new revenue participation right agreement, Apogee receives an upfront $100.0 million now, with the potential for additional tranches of $100.0 million, $200.0 million, and $250.0–$400.0 million tied to Phase 3 enrollment, positive Phase 3 results, and U.S. marketing approval by December 31, 2030.
The revenue share runs for 15 years from first approval, with tiered percentages on annual global zumilokibart sales. For Tier 1 sales up to $5 billion, the maximum combined revenue share can reach 3.4375%, declining at higher sales levels and subject to a $1.0 billion cap on Tranche 4‑related payments. Apogee and Blackstone also agreed to negotiate up to $500.0 million in senior debt.
Combined with Apogee’s existing $1.3 billion cash balance, management highlights up to $1.3 billion in flexible, largely non‑dilutive capital that it believes can support Phase 3 development and potential commercialization of zumilokibart. Following this deal, Apogee withdrew its prior cash runway end‑date guidance.
Apogee Therapeutics entered a major financing collaboration with Blackstone Life Sciences built around future sales of its anti‑IL‑13 antibody zumilokibart. Under a new revenue participation right agreement, Apogee receives an upfront $100.0 million now, with the potential for additional tranches of $100.0 million, $200.0 million, and $250.0–$400.0 million tied to Phase 3 enrollment, positive Phase 3 results, and U.S. marketing approval by December 31, 2030.
The revenue share runs for 15 years from first approval, with tiered percentages on annual global zumilokibart sales. For Tier 1 sales up to $5 billion, the maximum combined revenue share can reach 3.4375%, declining at higher sales levels and subject to a $1.0 billion cap on Tranche 4‑related payments. Apogee and Blackstone also agreed to negotiate up to $500.0 million in senior debt.
Combined with Apogee’s existing $1.3 billion cash balance, management highlights up to $1.3 billion in flexible, largely non‑dilutive capital that it believes can support Phase 3 development and potential commercialization of zumilokibart. Following this deal, Apogee withdrew its prior cash runway end‑date guidance.
Apogee Therapeutics reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The study met all primary and secondary endpoints with high statistical significance, including 65.9% of mid-dose patients achieving EASI-75, a 41.9% placebo-adjusted improvement. Zumilokibart was well tolerated with a safety profile consistent with other drugs in its class. Based on these data and prior Part A maintenance results, Apogee plans to advance the mid-dose into Phase 3 AD trials in the second half of 2026 and has outlined additional trials in asthma and eosinophilic esophagitis. The company also announced a strategic financing collaboration with Blackstone Life Sciences expected to fund development through potential commercialization of zumilokibart in AD, asthma, and EoE.
Apogee Therapeutics reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The study met all primary and secondary endpoints with high statistical significance, including 65.9% of mid-dose patients achieving EASI-75, a 41.9% placebo-adjusted improvement. Zumilokibart was well tolerated with a safety profile consistent with other drugs in its class. Based on these data and prior Part A maintenance results, Apogee plans to advance the mid-dose into Phase 3 AD trials in the second half of 2026 and has outlined additional trials in asthma and eosinophilic esophagitis. The company also announced a strategic financing collaboration with Blackstone Life Sciences expected to fund development through potential commercialization of zumilokibart in AD, asthma, and EoE.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on May 13, 2026 at weighted average prices of about $82.05 and $82.58 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the sales, Henderson continues to hold over one million Apogee Therapeutics shares, so the transactions represent a small portion of his overall position.